Open AccessThis article is
- freely available
Therapies from Fucoidan; Multifunctional Marine Polymers
Marinova Pty Ltd., 249 Kennedy Drive, Cambridge, Tasmania 7170, Australia
Received: 26 August 2011; in revised form: 22 September 2011 / Accepted: 26 September 2011 / Published: 30 September 2011
Abstract: Published research on fucoidans increased three fold between 2000 and 2010. These algal derived marine carbohydrate polymers present numerous valuable bioactivities. This review discusses the role for fucoidan in the control of acute and chronic inflammation via selectin blockade, enzyme inhibition and inhibiting the complement cascade. The recent data on toxicology and uptake of fucoidan is detailed together with a discussion on the comparative activities of fractions of fucoidan from different sources. Recent in vivo, in vitro and clinical research related to diverse clinical needs is discussed. Targets include osteoarthritis, kidney and liver disease, neglected infectious diseases, hemopoietic stem cell modulation, protection from radiation damage and treatments for snake envenomation. In recent years, the production of well characterized reproducible fucoidan fractions on a commercial scale has become possible making therapies from fucoidan a realizable goal.
Keywords: fucoidan; inflammation; fibrosis; viral infection
Citations to this Article
Cite This Article
MDPI and ACS Style
Fitton, J.H. Therapies from Fucoidan; Multifunctional Marine Polymers. Mar. Drugs 2011, 9, 1731-1760.
Fitton JH. Therapies from Fucoidan; Multifunctional Marine Polymers. Marine Drugs. 2011; 9(10):1731-1760.
Fitton, Janet Helen. 2011. "Therapies from Fucoidan; Multifunctional Marine Polymers." Mar. Drugs 9, no. 10: 1731-1760.